Buy or sell Trigemina stock pre IPO via an EquityZen fund
Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.
About Trigemina Stock
Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.
Chief Medical Officer
William Frey II
Chief Medical Advisor
Founder, Chief Scientist
David C Yeomans
Chief Financial Officer & Chief Operating Officer